[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_97":98},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","zkjgjjmk6dlmdj69izw3vxn8q","revision",2,"title","Silo Pharma 收购 Larry King 软件资产","originalTitle","Silo Pharma, Inc. (0001514183) (Filer)","summary","Silo Pharma 以 150,000 股普通股收购 Larry King 的软件及知识产权。交易股份设 12 个月锁定期，期间卖方不得转让。协议包含常见条款及卖方赔偿义务。","reason","source",{"_11":87,"_88":89,"_90":91,"_92":57,"_93":94,"_95":96},"links",{"_84":85,"_63":86},"publishedAt","2026-10-14T20:30:12.000Z","discoveredAt","2026-10-14T20:50:54.189Z","timelineAt","category","ai-products","tags",[81,82,83],"stockSymbols",[80],"score",32,"selected",false,"channel","news","story",{"_72":73,"_15":74},"x","readingMode","full","author","language","body",{"_76":-5,"_63":77,"_78":-5,"_79":40},"outline",[],"relatedStories",[75],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":68,"_69":70,"_71":70},"hasTranslation","bodyLanguage","original","factId","fnQ-hHabVSCo",{"_72":73,"_15":74},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","8a7b3909-d783-43e1-974c-841c01f01e38","Silo Pharma收购Larry King软件资产",{"_72":73,"_15":74},"zh","

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities\nExchange Act of 1934

Date of Report (Date of earliest event reported): October\n13, 2026

Silo Pharma, Inc.

(Exact name of registrant as specified in its charter)

\n \n \n \n \n \n \n \n \n \n \n \n \n

Nevada		001-41512		27-3046338
(State or other jurisdiction \nof incorporation)		(Commission File Number)		(IRS Employer \nIdentification No.)

\n \n \n \n \n \n \n \n \n

677 N. Washington Boulevard

Sarasota, FL

34236

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area\ncode: (718) 400-9031

N/A

(Former name or former address, if changed since last\nreport)

Check the appropriate box below if the Form 8-K filing\nis intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General\nInstruction A.2. below):

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Rule 12(b) of the\nAct:

\n \n \n \n \n \n \n \n \n \n \n \n \n

Title of each class		Trading Symbol(s)		Name of exchange on which registered
Common Stock, par value $0.0001 per share		SILO		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an\nemerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities\nExchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark\nif the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards\nprovided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement.

On October 13, 2026, Silo\nPharma, Inc. (the “Company”) entered into an asset purchase agreement (the “Agreement”) with Larry King (the “Seller”).\nPursuant to the Agreement, the Seller agreed to sell, and the Company agreed to purchase, certain software and related intellectual property\n(the “Purchased Assets”).

In consideration for the\nPurchased Assets, the Company issued to the Seller, 150,000 shares of its common stock, par value $0.0001 per share (the “Shares”).\nThe Shares are subject to a lock-up period beginning on the effective date of the Agreement and ending on the earlier of (i) twelve (12)\nmonths after such date, (ii) a Change in Control, as defined in the Agreement, or (iii) written consent of the Company (the “Lock\nUp Period”). During the Lock Up Period, the Seller may not, without the Company’s prior written consent, directly or indirectly,\noffer, sell, contract to sell, hedge, pledge, grant any option, right or warrant to purchase, or otherwise transfer or dispose of any\nof the Shares, or enter into any swap or other agreement or transaction that transfers, in whole or in part, directly or indirectly, the\neconomic consequence of ownership of any of the Shares.

The Agreement contains certain\nrepresentations, warranties and covenants of the parties that are customary for agreements of its type. In addition, the Seller agreed\nto indemnify the Company for any misrepresentation or breach under the Agreement, infringement of any third-party right by any portion\nof the software and any acts of gross negligence, fraud or intentional misconduct by the Seller.

The foregoing summary does\nnot purport to be complete and is qualified in its entirety by reference to the Agreement, a copy of which is filed as Exhibit 10.1 to\nthis Current Report on Form 8-K and incorporated herein by reference.

Item 3.02 Unregistered Sales of Equity Securities.

The information set forth under Item 1.01 is incorporated\nherein by reference.

The offer and sale to the Seller of the Shares was\nmade in reliance upon Section 4(a)(2) under the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

Item 9.01 Financial Statements\nand Exhibits.

(d) Exhibits.

\n \n \n \n \n \n \n \n \n \n \n \n \n

Exhibit No.		Description
10.1*		Asset Purchase Agreement, dated October 13, 2026, between the Company and Larry King.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

\n \n \n \n

*	The schedules (and similar attachments) to this exhibit have been omitted from this filing pursuant to Item 601(b)(10) of Regulation S-K. The Company agrees to furnish a supplemental copy of any omitted schedule (or similar attachment) to the Securities and Exchange Commission upon request.

SIGNATURES

Pursuant to the requirements of the Securities Exchange\nAct of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

	SILO PHARMA, INC.

Date: October 14, 2026	By:	/s/ Eric Weisblum
		Eric Weisblum
		Chief Executive Officer

","zhKind","complete","SILO","政策与监管","并购","公司与财报","aihot","/items/zkjgjjmk6dlmdj69izw3vxn8q","https://www.sec.gov/Archives/edgar/data/1514183/000121390026109457/0001213900-26-109457-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1792195200&sig=4eab1165515e57e2","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1792195200&sig=df95c58c297800b1 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1792195200&sig=2a4278e6e5e85947 96w","changelogVersion","2026-10-01T08:00"]